Literature DB >> 29441280

Pharmacological treatment of anxiety disorders in children and adolescents: a review for practitioners.

Dilip R Patel1, Cynthia Feucht2, Kelly Brown1, Jessica Ramsay1.   

Abstract

Anxiety disorders are common in children and adolescents with reported prevalence rates between 10% and 30%. A combined approach to treatment has been found to be the most effective for optimal outcomes and is typically comprised of psychotherapy (especially exposure-based cognitive behavior therapy), family and patient education, and use of medication if indicated. In children and adolescents who might benefit from use of medications, selective serotonin reuptake inhibitors (SSRIs) are the drugs of choice. The safety and efficacy of medications other than SSRIs in the treatment of children and adolescents with anxiety disorders are not fully established. Most children and adolescents respond well to treatment with long lasting resolution of symptoms, although, recurrence of the same, or development of a different type of anxiety disorder, is not uncommon. In most children and adolescents, anxiety disorders tend to persist into adulthood requiring long-term treatment planning. This paper reviews the pharmacological agents used in the treatment of anxiety disorders in children and adolescents.

Entities:  

Keywords:  Anxiety disorders; behavioral activation; bipolar switching; selective serotonin reuptake inhibitors (SSRIs); serotonin syndrome (SS)

Year:  2018        PMID: 29441280      PMCID: PMC5803020          DOI: 10.21037/tp.2017.08.05

Source DB:  PubMed          Journal:  Transl Pediatr        ISSN: 2224-4336


  43 in total

Review 1.  Psychopharmacology interventions for pediatric anxiety disorders: a research update.

Authors:  Bruce Waslick
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2006-01

2.  Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes.

Authors:  Graham J Emslie; Taryn Mayes; Giovanna Porta; Benedetto Vitiello; Greg Clarke; Karen Dineen Wagner; Joan Rosenbaum Asarnow; Anthony Spirito; Boris Birmaher; Neal Ryan; Betsy Kennard; Lynn DeBar; James McCracken; Michael Strober; Matthew Onorato; Jamie Zelazny; Marty Keller; Satish Iyengar; David Brent
Journal:  Am J Psychiatry       Date:  2010-05-17       Impact factor: 18.112

Review 3.  Assessment and treatment of anxiety disorders in children and adolescents.

Authors:  Anna M Wehry; Katja Beesdo-Baum; Meghann M Hennelly; Sucheta D Connolly; Jeffrey R Strawn
Journal:  Curr Psychiatry Rep       Date:  2015-07       Impact factor: 5.285

Review 4.  Psychopharmacologic treatment of pediatric anxiety disorders.

Authors:  Shauna P Reinblatt; John T Walkup
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2005-10

5.  Serotonergic agents in the treatment of social phobia in children and adolescents: a case series.

Authors:  C Mancini; M Van Ameringen; J M Oakman; P Farvolden
Journal:  Depress Anxiety       Date:  1999       Impact factor: 6.505

Review 6.  The Treatment for Adolescents With Depression Study (TADS): demographic and clinical characteristics.

Authors: 
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2005-01       Impact factor: 8.829

7.  Treatment for Adolescents with Depression Study (TADS): safety results.

Authors:  Graham Emslie; Christopher Kratochvil; Benedetto Vitiello; Susan Silva; Taryn Mayes; Steven McNulty; Elizabeth Weller; Bruce Waslick; Charles Casat; John Walkup; Sanjeev Pathak; Paul Rohde; Kelly Posner; John March
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2006-12       Impact factor: 8.829

8.  Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.

Authors:  David Brent; Graham Emslie; Greg Clarke; Karen Dineen Wagner; Joan Rosenbaum Asarnow; Marty Keller; Benedetto Vitiello; Louise Ritz; Satish Iyengar; Kaleab Abebe; Boris Birmaher; Neal Ryan; Betsy Kennard; Carroll Hughes; Lynn DeBar; James McCracken; Michael Strober; Robert Suddath; Anthony Spirito; Henrietta Leonard; Nadine Melhem; Giovanna Porta; Matthew Onorato; Jamie Zelazny
Journal:  JAMA       Date:  2008-02-27       Impact factor: 56.272

Review 9.  Clinical messages from the Treatment for Adolescents With Depression Study (TADS).

Authors:  John S March; Benedetto Vitiello
Journal:  Am J Psychiatry       Date:  2009-09-01       Impact factor: 18.112

10.  Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods.

Authors:  Scott N Compton; John T Walkup; Anne Marie Albano; John C Piacentini; Boris Birmaher; Joel T Sherrill; Golda S Ginsburg; Moira A Rynn; James T McCracken; Bruce D Waslick; Satish Iyengar; Phillip C Kendall; John S March
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2010-01-05       Impact factor: 3.033

View more
  3 in total

1.  Psychopharmacological Strategies Employing Guanfacine in an Adolescent Girl with Postural Orthostatic Tachycardia Syndrome and Severe Posttraumatic Stress Disorder.

Authors:  Stephanie Wu; Ari Morgenstern; Timothy Rice; Barbara Coffey
Journal:  J Child Adolesc Psychopharmacol       Date:  2022-05       Impact factor: 3.031

2.  Anxiety related disorders in adolescents in the United Arab Emirates: a population based cross-sectional study.

Authors:  Nabeel Al-Yateem; Wegdan Bani Issa; Rachel C Rossiter; Arwa Al-Shujairi; Hadia Radwan; Manal Awad; Randa Fakhry; Ibrahim Mahmoud
Journal:  BMC Pediatr       Date:  2020-05-25       Impact factor: 2.125

Review 3.  Therapeutic Potential of Exogenous Ketone Supplement Induced Ketosis in the Treatment of Psychiatric Disorders: Review of Current Literature.

Authors:  Zsolt Kovács; Dominic P D'Agostino; David Diamond; Mark S Kindy; Christopher Rogers; Csilla Ari
Journal:  Front Psychiatry       Date:  2019-05-23       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.